ReviewG-protein coupled receptors as therapeutic targets for neurodegenerative and cerebrovascular diseases

- Neurological disorders are still devastating to sufferers and their families, and perplexing to scientists and clinicians.
- Role of G-protein coupled receptors (GPCRs) in the pathogenesis of neurodegenerative and cerebrovascular diseases.
- The potential use of GPCRs as therapeutic targets for neurodegenerative and cerebrovascular diseases.

Neurodegenerative and cerebrovascular diseases are frequent in elderly populations and comprise primarily of dementia (mainly Alzheimer's disease) Parkinson's disease and stroke. These neurological disorders (NDs) occur as a result of neurodegenerative processes and represent one of the most frequent causes of death and disability worldwide with a significant clinical and socio-economic impact. Although NDs have been characterized for many years, the exact molecular mechanisms that govern these pathologies or why they target specific individuals and specific neuronal populations remain unclear. As research progresses, many similarities appear which relate these diseases to one another on a subcellular level. Discovering these similarities offers hope for therapeutic advances that could ameliorate the conditions of many diseases simultaneously. G-protein coupled receptors (GPCRs) are the most abundant receptor type in the central nervous system and are linked to complex downstream pathways, manipulation of which may have therapeutic application in many NDs. This review will highlight the potential use of neurotransmitter GPCRs as emerging therapeutic targets for neurodegenerative and cerebrovascular diseases.